CDK4/6 inhibitors
From 9 Approvals to Price Wars: The Changing CDK4/6 Landscape in China and Its U.S. Contrast
With 9 CDK4/6 approvals and over 20 palbociclib generics, China’s oncology market is entering a phase of intense competition and price erosion. Meanwhile, the U.S. market stays concentrated under palbociclib, ribociclib, and abemaciclib, where strong patents keep generics at bay.